GENMAB A/S -SP ADR (GMAB) Stock Fundamental Analysis

NASDAQ:GMAB • US3723032062

30.03 USD
+0.44 (+1.49%)
At close: Feb 13, 2026
30.42 USD
+0.39 (+1.3%)
Pre-Market: 2/17/2026, 6:16:23 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Overall GMAB gets a fundamental rating of 7 out of 10. We evaluated GMAB against 521 industry peers in the Biotechnology industry. GMAB scores excellent points on both the profitability and health parts. This is a solid base for a good stock. GMAB is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make GMAB suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

7

1. Profitability

1.1 Basic Checks

  • In the past year GMAB was profitable.
  • GMAB had a positive operating cash flow in the past year.
  • Each year in the past 5 years GMAB has been profitable.
  • In the past 5 years GMAB always reported a positive cash flow from operatings.
GMAB Yearly Net Income VS EBIT VS OCF VS FCFGMAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

1.2 Ratios

  • The Return On Assets of GMAB (21.10%) is better than 97.31% of its industry peers.
  • The Return On Equity of GMAB (25.76%) is better than 96.74% of its industry peers.
  • With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.74% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 18.54%.
  • The 3 year average ROIC (15.20%) for GMAB is below the current ROIC(17.11%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROIC 17.11%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
GMAB Yearly ROA, ROE, ROICGMAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

1.3 Margins

  • GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.31% of its industry peers.
  • GMAB's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 36.85%, GMAB belongs to the top of the industry, outperforming 97.70% of the companies in the same industry.
  • GMAB's Operating Margin has declined in the last couple of years.
  • The Gross Margin of GMAB (94.27%) is better than 94.82% of its industry peers.
  • In the last couple of years the Gross Margin of GMAB has declined.
Industry RankSector Rank
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
GMAB Yearly Profit, Operating, Gross MarginsGMAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), GMAB is creating value.
  • Compared to 1 year ago, GMAB has less shares outstanding
  • Compared to 5 years ago, GMAB has less shares outstanding
  • GMAB has a worse debt/assets ratio than last year.
GMAB Yearly Shares OutstandingGMAB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GMAB Yearly Total Debt VS Total AssetsGMAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 11.31 indicates that GMAB is not in any danger for bankruptcy at the moment.
  • GMAB's Altman-Z score of 11.31 is amongst the best of the industry. GMAB outperforms 84.26% of its industry peers.
  • The Debt to FCF ratio of GMAB is 0.12, which is an excellent value as it means it would take GMAB, only 0.12 years of fcf income to pay off all of its debts.
  • GMAB has a Debt to FCF ratio of 0.12. This is amongst the best in the industry. GMAB outperforms 95.39% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of GMAB (0.02) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Altman-Z 11.31
ROIC/WACC2.34
WACC7.32%
GMAB Yearly LT Debt VS Equity VS FCFGMAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.3 Liquidity

  • A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 6.03, GMAB is doing good in the industry, outperforming 62.96% of the companies in the same industry.
  • GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 6.01, GMAB is doing good in the industry, outperforming 63.72% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.03
Quick Ratio 6.01
GMAB Yearly Current Assets VS Current LiabilitesGMAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 125.90% over the past year.
  • GMAB shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 28.38% yearly.
  • The Revenue has grown by 24.66% in the past year. This is a very strong growth!
  • GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%

3.2 Future

  • GMAB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.70% yearly.
  • GMAB is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.39% yearly.
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
GMAB Yearly Revenue VS EstimatesGMAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2B 4B 6B
GMAB Yearly EPS VS EstimatesGMAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

6

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.72, GMAB is valued correctly.
  • Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 97.50% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of GMAB to the average of the S&P500 Index (27.19), we can say GMAB is valued rather cheaply.
  • Based on the Price/Forward Earnings ratio of 17.64, the valuation of GMAB can be described as rather expensive.
  • 93.67% of the companies in the same industry are more expensive than GMAB, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (28.06), we can say GMAB is valued slightly cheaper.
Industry RankSector Rank
PE 12.72
Fwd PE 17.64
GMAB Price Earnings VS Forward Price EarningsGMAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, GMAB is valued cheaper than 97.50% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, GMAB is valued cheaply inside the industry as 96.74% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 15.37
EV/EBITDA 9.79
GMAB Per share dataGMAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates GMAB does not grow enough to justify the current Price/Earnings ratio.
  • The decent profitability rating of GMAB may justify a higher PE ratio.
PEG (NY)1.98
PEG (5Y)0.45
EPS Next 2Y-1.8%
EPS Next 3Y6.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • GMAB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENMAB A/S -SP ADR

NASDAQ:GMAB (2/13/2026, 8:13:37 PM)

Premarket: 30.42 +0.39 (+1.3%)

30.03

+0.44 (+1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-05
Earnings (Next)05-07
Inst Owners44.16%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.50B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts73.08
Price Target47.44 (57.98%)
Short Float %1.42%
Short Ratio5.15
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)30.75%
Min EPS beat(2)25.14%
Max EPS beat(2)36.36%
EPS beat(4)4
Avg EPS beat(4)61.45%
Min EPS beat(4)25.14%
Max EPS beat(4)134.67%
EPS beat(8)6
Avg EPS beat(8)30.99%
EPS beat(12)8
Avg EPS beat(12)16.81%
EPS beat(16)12
Avg EPS beat(16)30.22%
Revenue beat(2)1
Avg Revenue beat(2)-0.2%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.09%
Revenue beat(4)2
Avg Revenue beat(4)-1.55%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)300.02%
Revenue beat(12)10
Avg Revenue beat(12)350.69%
Revenue beat(16)14
Avg Revenue beat(16)264.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0.11%
EPS NQ rev (3m)1.97%
EPS NY rev (1m)3.51%
EPS NY rev (3m)7.6%
Revenue NQ rev (1m)0.95%
Revenue NQ rev (3m)-0.38%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.05%
Valuation
Industry RankSector Rank
PE 12.72
Fwd PE 17.64
P/S 5.16
P/FCF 15.37
P/OCF 14.51
P/B 3.22
P/tB 5.07
EV/EBITDA 9.79
EPS(TTM)2.36
EY7.86%
EPS(NY)1.7
Fwd EY5.67%
FCF(TTM)1.95
FCFY6.51%
OCF(TTM)2.07
OCFY6.89%
SpS5.82
BVpS9.34
TBVpS5.92
PEG (NY)1.98
PEG (5Y)0.45
Graham Number22.27
Profitability
Industry RankSector Rank
ROA 21.1%
ROE 25.76%
ROCE 21.02%
ROIC 17.11%
ROICexc 37.46%
ROICexgc 140.29%
OM 36.85%
PM (TTM) 41.35%
GM 94.27%
FCFM 33.59%
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF 0.12
Debt/EBITDA 0.09
Cap/Depr 106.94%
Cap/Sales 1.98%
Interest Coverage 243.04
Cash Conversion 91.92%
Profit Quality 81.24%
Current Ratio 6.03
Quick Ratio 6.01
Altman-Z 11.31
F-Score7
WACC7.32%
ROIC/WACC2.34
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)125.9%
EPS 3Y34.24%
EPS 5Y28.38%
EPS Q2Q%121.44%
EPS Next Y6.42%
EPS Next 2Y-1.8%
EPS Next 3Y6.27%
EPS Next 5Y11.7%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.77%
Revenue Next 2Y19.6%
Revenue Next 3Y17.39%
Revenue Next 5Y14.39%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year56.34%
EBIT Next 3Y28.03%
EBIT Next 5Y19.44%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%

GENMAB A/S -SP ADR / GMAB FAQ

What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?

ChartMill assigns a fundamental rating of 7 / 10 to GMAB.


What is the valuation status for GMAB stock?

ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.


Can you provide the profitability details for GENMAB A/S -SP ADR?

GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for GMAB stock?

The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 12.72 and the Price/Book (PB) ratio is 3.22.


Can you provide the financial health for GMAB stock?

The financial health rating of GENMAB A/S -SP ADR (GMAB) is 8 / 10.